Royce & Associates LP Buys 41,996 Shares of Definium Therapeutics, Inc. $DFTX

Royce & Associates LP increased its stake in shares of Definium Therapeutics, Inc. (NASDAQ:DFTX – Free Report) by 20.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 250,547 shares of the company’s stock after purchasing an additional 41,996 shares during the quarter. Royce & Associates LP owned 0.19% of Definium Therapeutics worth $9,536,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of DFTX. Wellington Management Group LLP purchased a new position in shares of Definium Therapeutics in the 2nd quarter valued at about $138,755,000. Seven Fleet Capital Management LP acquired a new position in shares of Definium Therapeutics during the second quarter worth about $6,992,000. Moody Aldrich Partners LLC grew its position in shares of Definium Therapeutics by 191.8% during the third quarter. Moody Aldrich Partners LLC now owns 148,870 shares of the company’s stock worth $5,666,000 after buying an additional 97,845 shares in the last quarter. Sequoia Financial Advisors LLC purchased a new stake in shares of Definium Therapeutics during the second quarter worth approximately $812,000. Finally, TD Waterhouse Canada Inc. purchased a new stake in shares of Definium Therapeutics during the second quarter worth approximately $1,592,000. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Definium Therapeutics Trading Down 2.6%

DFTX opened at $29.38 on Wednesday. Definium Therapeutics, Inc. has a one year low of $10.46 and a one year high of $49.70. The company has a market cap of $4.02 billion, a P/E ratio of -9.45 and a beta of 2.23. The company has a debt-to-equity ratio of 0.04, a quick ratio of 15.53 and a current ratio of 15.53. The business’s 50-day simple moving average is $35.74 and its 200-day simple moving average is $30.51.

Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.09. As a group, equities research analysts expect that Definium Therapeutics, Inc. will post -2.94 EPS for the current fiscal year.

Insider Activity at Definium Therapeutics

In other news, CFO Brandi Roberts sold 3,377 shares of the company’s stock in a transaction on Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $123,496.89. Following the completion of the transaction, the chief financial officer owned 394,528 shares in the company, valued at approximately $14,427,888.96. This represents a 0.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert Barrow sold 31,550 shares of the stock in a transaction on Friday, September 25th. The shares were sold at an average price of $36.57, for a total transaction of $1,153,783.50. Following the completion of the transaction, the chief executive officer directly owned 2,213,090 shares in the company, valued at $80,932,701.30. This trade represents a 1.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 71,098 shares of company stock worth $2,626,115. Corporate insiders own 2.40% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on DFTX. Canaccord Genuity Group set a $78.00 target price on shares of Definium Therapeutics and gave the company a “buy” rating in a report on Tuesday, September 15th. Robert W. Baird boosted their price target on shares of Definium Therapeutics from $75.00 to $79.00 and gave the stock an “outperform” rating in a report on Tuesday, September 15th. Oppenheimer reissued an “outperform” rating and issued a $75.00 price objective on shares of Definium Therapeutics in a research report on Monday, September 14th. Maxim Group set a $55.00 price objective on shares of Definium Therapeutics and gave the company a “buy” rating in a report on Friday, August 14th. Finally, Royal Bank Of Canada lifted their price objective on shares of Definium Therapeutics from $66.00 to $70.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 10th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $66.29.

Get Our Latest Stock Analysis on DFTX

About Definium Therapeutics

(Free Report)

Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026.

Read More

Institutional Ownership by Quarter for Definium Therapeutics (NASDAQ:DFTX)

Receive News & Ratings for Definium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.